Stockscreener 앱 받기
6.92
3.70%
0.1314
전일 마감가:
$6.7886
열려 있는:
$6.99
하루 거래량:
3,483
Relative Volume:
0.29
시가총액:
$6.33M
수익:
-
순이익/손실:
$-34.66M
주가수익비율:
-0.071
EPS:
-97.5284
순현금흐름:
$-19.52M
1주 성능:
-3.83%
1개월 성능:
-20.99%
6개월 성능:
-23.81%
1년 성능:
-7.97%
1일 변동 폭
$6.75
$7.0133
1주일 범위
$6.5001
$7.48
52주 변동 폭
$6.0829
$20.99
트랜스코드 테라 Stock (RNAZ) Company Profile
명칭
Transcode Therapeutics Inc
전화
857-301-6857
주소
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
6.90 | 6.39M | 0 | -34.66M | -19.52M | -97.53 |
VRTX
Vertex Pharmaceuticals Inc
|
441.11 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.76 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.22 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
290.73 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
143.78 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
트랜스코드 테라 주식(RNAZ)의 최신 뉴스
Mesa Air Group, Inc.Common Stock (NQ: MESA - FinancialContent
What you need to know before buying TransCode Therapeutics (RNAZ) (Breakdown Watch) 2026-05-11Analyst Upgrade - newser.com
What TransCode Therapeutics (RNAZ) flagged as biggest challenges ahead | Q4 2024: Below ExpectationsCommunity Buy Signals - newser.com
Trading Systems Reacting to (RNAZ) Volatility - Stock Traders Daily
TransCode Therapeutics (RNAZ) asks shareholders to OK preferred conversions, SEPA funding - Stock Titan
How TransCode Therapeutics (RNAZ) differentiates itself from competitors (Near Highs) 2026-05-08Open Stock Signal Network - newser.com
RNAZ Stock Price, Quote & Chart | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
TransCode Therapeutics 2025 10-K/A: Executive Compensation, Board Members, and Corporate Governance Overview - Minichart
TransCode Registers 1.53 Million Shares for YA II PN Resale Under Equity Purchase Deal - marketscreener.com
TransCode Therapeutics (NASDAQ: RNAZ) registers 15.96M resale shares by selling holders - Stock Titan
TransCode Therapeutics (NASDAQ: RNAZ) updates 2025 governance, executive pay and ownership - Stock Titan
MSN Money - MSN
TransCode Therapeutics (NASDAQ: RNAZ) sets up 1.53M-share SEPA resale - Stock Titan
TransCode names Anna Moore scientific board chair - Investing.com UK
TransCode Therapeutics Appoints Dr. Anna Moore as Scientific Advisory Board Chair, Signs Research Agreement with Michigan State University - citybuzz -
TransCode names Anna Moore scientific board chair By Investing.com - Investing.com Australia
Transcode Therapeutics appoints Dr. Anna Moore as chair of scientific advisory board - marketscreener.com
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University - PR Newswire
RNAZ News | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
TransCode Therapeutics signs financing deal worth up to $20 million - MSN
RNAZ (TransCode Therapeutics Inc.) posts far wider than expected Q4 2024 loss, shares notch small gain in today’s trading.Asset Sale - Xã Thanh Hà
TransCode Therapeutics (RNAZ) Stock: Volatility Overview (-4.45%) 2026-04-22Social Buzz - Cổng thông tin điện tử tỉnh Lào Cai
YA II affiliates report 101,772 shares in TransCode Therapeutics (RNAZ) under convertible note - Stock Titan
(RNAZ) and the Role of Price-Sensitive Allocations - Stock Traders Daily
TransCode Therapeutics 2025 10-K: Advancing RNA and Immuno-Oncology Cancer Therapeutics with Proprietary TTX Platform - Minichart
TransCode Therapeutics (RNAZ) Stock Dual Listing (Smart Money Flows) 2026-04-15Verified Signals - Cổng thông tin điện tử Tỉnh Sơn La
TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
TransCode Therapeutics (NASDAQ: RNAZ) expands cancer pipeline with Polynoma and Unleash deals - Stock Titan
TransCode Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aug Weekly: Is TransCode Therapeutics Inc showing insider buying2026 Major Catalysts & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Geopolitics Watch: Can TransCode Therapeutics Inc sustain its profitability - baoquankhu1.vn
Chipmakers Recap: Is TransCode Therapeutics Inc a good stock for dollar cost averaging2026 Macro Moves & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Big Picture: What is TransCode Therapeutics Incs P E ratio telling us2026 Earnings & Real-Time Buy Signal Alerts - baoquankhu1.vn
Insider Sell: Why is TransCode Therapeutics Inc stock going downEarnings Growth Report & Stock Portfolio Risk Management - baoquankhu1.vn
TransCode Therapeutics Secures New Financing to Extend Runway - The Globe and Mail
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 - Bitget
TransCode Therapeutics Secures Up to $20 Million Financing for Metastatic Cancer Trial - citybuzz -
TransCode Therapeutics Secures Up to $20 Million Flexible Financing to Advance Lead Cancer Program and Extend Runway Into 2028 - Minichart
Eightco (NASDAQ: ORBS) Represents the Biggest Public Market Exposure to OpenAI for Retail Investors - Weekly Voice
TransCode Therapeutics Secures $20M Financing - citybiz
Transcode Therapeutics Secures Up To $14 Million Standby Equity Facility and $6 Million Notes With Yorkville - TradingView — Track All Markets
TransCode Therapeutics (NASDAQ: RNAZ) lines up up to $20M in new flexible funding - Stock Titan
Market Overview: How sensitive is TransCode Therapeutics Inc to inflationWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Form 8-KCurrent report - ADVFN
Responsive Playbooks and the RNAZ Inflection - Stock Traders Daily
RNAZ PE Ratio & Valuation, Is RNAZ Overvalued - Intellectia AI
TransCode Therapeutics, Inc. (RNAZ) Competitors - Meyka
TransCode Therapeutics Delays 2025 Annual Filing - The Globe and Mail
Bank Watch: Is TransCode Therapeutics Inc attractive for institutional investorsTrade Analysis Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
Is TransCode Therapeutics Inc attractive for institutional investorsWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
RNAZ (RNAZ) delays 2025 Form 10-K after $25M preferred placement and acquisition - Stock Titan
트랜스코드 테라 (RNAZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.44%
자본화:
|
볼륨(24시간):